Cargando…
Emerging Strategies in TCR-Engineered T Cells
Immunotherapy of cancer has made tremendous progress in recent years, as demonstrated by the remarkable clinical responses obtained from adoptive cell transfer (ACT) of patient-derived tumor infiltrating lymphocytes, chimeric antigen receptor (CAR)-modified T cells (CAR-T) and T cell receptor (TCR)-...
Autores principales: | Wei, Fang, Cheng, Xiao-Xia, Xue, John Zhao, Xue, Shao-An |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006933/ https://www.ncbi.nlm.nih.gov/pubmed/35432319 http://dx.doi.org/10.3389/fimmu.2022.850358 |
Ejemplares similares
-
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
por: Shafer, Paul, et al.
Publicado: (2022) -
Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons
por: Zhao, Qijie, et al.
Publicado: (2021) -
TCR-engineered T cells: A model of inducible TCR expression to dissect the interrelationship between two TCRs
por: Reuß, Simone, et al.
Publicado: (2014) -
Preclinical Studies of the Off-Target Reactivity of AFP(158)-Specific TCR Engineered T Cells
por: Cai, Lun, et al.
Publicado: (2020) -
GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR
por: Straetemans, Trudy, et al.
Publicado: (2018)